Skip to main content
. Author manuscript; available in PMC: 2023 Nov 26.
Published in final edited form as: Annu Rev Pharmacol Toxicol. 2021 Sep 27;62:595–616. doi: 10.1146/annurev-pharmtox-052120-011012

Figure 4. ChIP-seq.

Figure 4.

(A) ChIP-seq procedure. (B) ChIP-seq using an antibody to RNA Polymerase II (Polr2a) reports occupancy of RNA Polymerase II complex over Aqp2 gene in presence and absence of V2 receptor selective vasopressin analog dDAVP. (C) Plot of transcript abundance ratio (dDAVP/Vehicle) versus RNA Polymerase II occupancy ratio (dDAVP/Vehicle) shows that only a few genes are regulated transcriptionally in response to V2 vasopressin receptor binding.